Position in TRVI
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$1,678,500
+$604,800 QoQ
Shares Held
90,000
0.0% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#88
of 218 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Erste Asset Management GmbH holds $553,204,959 across 68 Biotechnology names. TRVI ranks #42 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,154,900 | $79,968,339 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
110,210 | $59,177,259 | |
| 3 | SRPT |
Sarepta Therapeutics, Inc.
|
2,568,945 | $46,163,941 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
76,558 | $38,028,654 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
834,000 | $29,515,260 | |
| 6 | DNA |
Ginkgo Bioworks Holdings, Inc.
|
2,536,939 | $25,141,065 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
38,716 | $24,140,974 | |
| 8 | MIRM |
Mirum Pharmaceuticals, Inc.
|
205,000 | $23,999,350 |
All Filings in TRVI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,678,500 | 90,000 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $1,073,700 | 90,000 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,126,800 | 90,000 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||